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Screening cocktails of candidate genes for induction of pluripotency and self-renewal in nonstem cells has
identified a surprising new embryonic stem cell regulator, themyc proto-oncogene. Here the possible mech-
anisms by which myc controls self-renewal and pluripotency are discussed.The Search for the Cellular Fountain of Youth:
Pluripotency and Self-Renewal Factors
Over the years, the puzzle of the molecular determinants of plu-
ripotency and self-renewal in stem cells has been approached
in a gene-by-gene fashion. This piecemeal method used con-
ventional functional studies of genes whose expression patterns
or knockout (KO) phenotypes suggested possible stem cell func-
tions. Several years ago, gene expression screens, including mi-
croarrays, functional libraries, and differential display, began to
be used to identify genes enriched in stem cells versus nonstem
cells. Despite the strength of these screening methods in their
unbiased, relatively global searching capacity, they produced
very long lists of genes enriched in stem cells. The prospect
of fishing out new stem cell regulatory molecules from this sea
of genes seemed daunting. Nonetheless, some familiar faces ap-
peared near the top of such lists, including Oct3/4 and Sox2,
suggesting the methods and data were inherently valid (Kelly
and Rizzino, 2000; Ramalho-Santos et al., 2002).
Many other geneswere alsoon these lists that hadnot been pre-
viously thought to be important stem cell regulators. For example,
the N-myc (alsoMYCN) proto-oncogene was very highly enriched
inanumberof stemcells (Kelly andRizzino, 2000;Ramalho-Santos
et al., 2002), including hematopoietic as well as both human and
murine embryonic stem cells (HSCs, hESCs, and mESCs, respec-
tively). However, unlike Nanog, both N-myc and its more famous
relative c-myc had been intensively studied for almost two de-
cades, raising the question of what if anything was already known
about myc function in stem cells. In fact, around the same time
as the microarray studies, c- and N-myc conditional KO mice
with disruption targeted to stem cells were used to explore myc
function in somatic stem cells (Knoepfler et al., 2002; Wilson
et al., 2004). For example, KO studies indicated N-mycwas abso-
lutely required for normal neural stemcell (NSC) function (Knoepfler
et al., 2002). c-myc appeared to influence HSC interactionwith the
nichesuch that theKOresulted inasurprising increase inHSCpop-
ulations (Wilson et al., 2004). These unexpected results and the
coexpression of both c- and N-myc in HSCs leave the precise na-
ture ofmyc’s role in HSC function open at this point. Subsequently,
Dalton’s group demonstrated an essential role for c-myc in normal
LIF signaling in mESCs and showed that enforced c-myc expres-
sion conferred LIF-independent ESC growth (Cartwright et al.,
2005), sparking great interest inmyc function specifically in ESCs.18 Cell Stem Cell 2, January 2008 ª2008 Elsevier Inc.The Fantastic Four and More
Defining the uniquemolecular determinants of stem cell function,
particularly that of ESCs, is critically important for understanding
how to maintain or manipulate stem cell behavior. However,
such information also brings the exciting possibility of converting
nonstem cells into stem cells. Such a transformation would have
enormous therapeutic implications for regenerative medicine,
particularly personalized stem cell therapies. Yamanaka’s group
provided a major leap in that direction in their studies that intro-
ducedmixtures or ‘‘cocktails’’ of genes into murine fibroblasts to
measure whether any of the combinations of their 24 total candi-
date factors could yield what they termed ‘‘induced pluripotent
stem (iPS) cells’’ (Takahashi and Yamanaka, 2006). Because
Dalton had implicated myc in ESC function, the Yamanaka lab
included myc in the pool of 24 candidates. This approach paid
off when they hit upon one special cocktail of four factors, which
together with selection for Fbx15 expression, could produce the
desired iPS cell production. The four genes included two of the
most well-established ESC factors, Oct3/4 and Sox2, and also
two surprising new additions: Klf4 and c-myc.
Several recent papers have recapitulated and extended the
initial iPS cell murine studies (Maherali et al., 2007; Okita et al.,
2007; Wernig et al., 2007). The first iPS cells lacked the ability
to contribute to the germline when injected into blastocysts. In
contrast, the newer iPS cells containing the same four factors
now also selected for Nanog expression instead of Fbx15 were
more fully reprogrammed and possessed the ability to contribute
to the germline. What can Nanog do that Fbx15 cannot? A key,
unique attribute of the newer iPS cells is their overall ESC signa-
tures of chromatin modifications. This epigenetic programming
in turn appears responsible for ESC-like gene expression pat-
terns present only in the newer iPS cells and induced by Nanog
in some as yet uncharacterizedmanner. Thus, althoughNanog is
dispensable for iPS cell formation per se, it is essential for full
reprogramming.
A Step Closer to Safe Regenerative Medicine:
Human iPS Cells with and without myc
Two recent studies from the groups of Yamanaka and Thomson
have succeeded in generating iPS cell clones by direct reprog-
ramming of human fibroblasts (Takahashi et al., 2007; Yu et al.,
2007). These findings were met with a wide fanfare of media
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closer to therapeutic development. Progress toward answering
some key questions about myc function in iPS cell formation
has now been reported in additional papers from the Yamanaka
and Jaenisch groups. These studies report iPS cell production
with a three-factor cocktail that does not includemyc (Nakagawa
et al., 2007; Wernig et al., 2008) and was possible also in human
iPS cells (Nakagawa et al., 2007). The efficiency of the iPS cell
process without myc is dramatically reduced and appears to
progress much more slowly. Indeed, under standard antibiotic
selection, the iPS cell process failed without myc. In half of the
experiments conducted over an extended period of selection,
no iPS cell colonies at all were produced when myc was ex-
cluded from the reprogramming protocol. An example of suc-
cessful iPS cell formation without myc, from adult tail tip fibro-
blasts, nonetheless yielded iPS cells with an almost 500-fold
reduced efficiency, demonstrating that, at least under these
assay conditions, myc fulfils an important role in the direct re-
programming process (Nakagawa et al., 2007). Thus, the ability
to routinely and efficiently generate iPS cells may bemyc depen-
dent. Of great importance is the observation that mice generated
from these three-factor iPS cells did not develop any tumors
within 100 days (Nakagawa et al., 2007), indicating that not all
iPS cell-derived mice are prone to tumors. Although long-term
studies of tumorigenicity in thesemice have yet to be conducted,
this finding is nonetheless a significant advance in that it estab-
lishes myc as a key determinant of iPS cell tumorigenicity and
suggests the tumorigenicity of iPS cells can be reduced.
In one of the reports of human iPS cells, Thomson’s group
tested the ability of quartets of factors from a group of 14 candi-
dates, importantly not including c-myc, to induce human iPS cell
formation. They found that Oct3/4, Sox2, Nanog, and Lin28
could reprogram human neonatal somatic cells (Yu et al.,
2007), although Lin28 was not strictly required, and iPS cell
induction of fibroblasts from adult human cells was not tested.
Still, this study provides yet another example of induced pluripo-
tency without exogenous c-myc. However, because Thomson
did not include c-myc in their group of 14 candidate factors,
it is unclear whether c-myc would have been selected as a com-
ponent of their successful screen. Given the findings from the
most recent Yamanaka paper, it would be interesting to deter-
mine whether the addition of c-myc as a fifth factor in Thomson’s
cocktail would substantially boost the efficiency of human iPS
cell formation.
An additional unresolved point raised by the recent Thomson
and Yamanaka results is whether the iPS cells generated without
exogenous myc have, in fact, been selected in culture based
partially on their endogenousmyc levels. Indeed, the issue of en-
dogenousmyc complicates interpretation of the observations of
iPS cell formation without added myc. myc may very well be in-
dispensable for iPS cell formation, as iPS cells produced without
added myc continue to express endogenous c-myc (Nakagawa
et al., 2007), which may in effect fill in for the omitted exogenous
c-myc, albeit with a lower efficiency. Also it remains unknown if
iPS cells generated without added c-myc may have been se-
lected for high levels of endogenous N- or L-myc (Blelloch
et al., 2007; Nakagawa et al., 2007), now also proven to drive
iPS cell formation much the same as c-myc. Determining the
mechanisms by which myc drives efficient iPS cell formationmay open the door to findingways to efficiently produce iPS cells
without myc, for example by substituting another nontumori-
genic factor or by treatment of cells with a pharmacological
agent. Such an effort should be greatly aided by comparisons
of existing iPS cells generated with and without added c-myc.
Whymyc?
While studies addressing the open questions outlined above are
conducted, we can model the role played by myc in the iPS cell
process based on what is already known. c-myc was one of the
first proto-oncogenes identified, and the myc family, including
N-myc and L-myc, has proven to have a potent role in most
human cancers when expression is deregulated. How could
a proto-oncogene contribute to pluripotency or self-renewal of
ESCs? Three models are proposed (Figure 1): (1) inducing
a cell-cycle program necessary specifically for self-renewal, (2)
modifying epigenetic patterns to promote dedifferentiation or
block additional differentiation, and (3) selection of a rare popu-
lation of cells with predetermined traits suited to permit induced
pluripotency and self-renewal. Recent studies onmyc function in
somatic stem cells as well as ESCs support aspects of each
model as outlined below and, together, most strongly support
a combination model incorporating aspects of each of the
specific hypotheses (Figure 1).
Jump Starting the Cell Cycle
Self-renewal is an essential hallmark of stem cell function and
necessitates entrance into the cell cycle, after which at least
one resulting daughter cell maintains the parental differentiation
capacity as well as the potential for subsequent self-renewing
divisions. In this first model, myc pushes differentiated cells to
enter the cell cycle in a manner consistent with self-renewal,
as required to achieve pluripotency. One or more of the other
three factors in the cocktail may cooperate with myc to sustain
cycling that promotes self-renewal. This model is particularly
attractive given the compelling links between myc and the cell
cycle in a host of different cell types, but is there evidence of reg-
ulation of the cell cycle specifically in stem cells bymyc? This is,
in fact, the case, as studies of a conditional KO of the N-myc
gene in NSCs using nestin-cre indicated that N-myc NSC KO
mice displayed a failure of normal brain growth (Knoepfler
et al., 2002). This phenotype was traced to a reduction in NSC
populations that was in turn linked to disruptions of an NSC
cell-cycle regulatory program. Loss of N-myc resulted in high
levels of the cyclin-dependent kinase inhibitors (CDKI)
p18INK4c and p27KIP1 and strikingly decreased expression of
cyclin D2. Thus, a key role for N-myc in NSCs is control of
a gene expression program involving cell-cycle regulators that
is central for maintenance of self-renewal and inhibition of differ-
entiation. myc may induce a stem-like cell-cycle program in
fibroblasts similar to what was observed in NSCs whereby myc
represses CDKI and stimulates D cyclins. The unique cell-cycle
regulatory pathway in ESCs may be explained by a combination
of low CDKI levels, high Cdk2 activity, and Rb hyperphosphory-
lation together maintained by elevated myc (Cartwright et al.,
2005). Also importantly, c-myc, albeit exogenous, sustained
self-renewal in ESCs without strongly impinging on the cell cycle
and was postulated to function by blocking differentiation (Cart-
wright et al., 2005). Results generated with N-myc are likely to
extend to c-myc, given that N-myc could replace the requirementCell Stem Cell 2, January 2008 ª2008 Elsevier Inc. 19
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Nakagawa et al., 2007). Analyzing the cell-cycle properties of
the different iPS cell lines generated with and without varying
levels ofmyc and comparing them to ESC should provide further
insight into this model.
Chromatin Reprogramming
According to this second paradigm, myc contributes to iPS cell
formation by inducing chromatin changes required for pluripo-
tency (reviewed in Yamanaka, 2007). Although the Myc protein
has long been modeled as a classic gene-specific transcription
factor that acts strictly at the promoters of genes via its histone
acetyltransferase cofactors, two recent lines of investigation
challenge this assumption. Several studies of genomic binding
in cell lines consistently indicate that Myc exhibits a strikingly
widespread profile of DNA binding, likely to tens of thousands
of sites (reviewed in Knoepfler, 2007). Unfortunately, none of
these studies were conducted in stem cells. However, Myc
was also recently found to possess global chromatin activating
function in NSCs (Knoepfler et al., 2006), consistent with its
widespread genomic binding in other cell types. Indeed, a strik-
ing phenotype of N-myc-deficient NSCs was a profound alter-
ation of their nuclear structure and global histone modifications.
NSCs lacking N-myc had condensed, highly heterochromatic
nuclei, indicating that N-Myc plays a normal role in the wide-
spread maintenance of key components of active chromatin,
including acetylated histone H3 and H4 as well as H3methylated
at lysine 4. Global chromatin inactivation in tumors when myc
was shut off (Wu et al., 2007) is consistent with the global chro-
matin function for myc reported in NSCs.
A widespread impact on chromatin function by Myc could
contribute to iPS cell formation through direct activation of genes
important for pluripotency or self-renewal, as well as blockage
of differentiation. Support for this hypothesis comes from studies
of ESCs, where decreased myc activity induced differentiation
(Cartwright et al., 2005), and from analyses of N-myc-deficient
Figure 1. Models of Myc Function in iPS
Cell Formation
Models of three potential mechanisms by which
Myc induces iPS cell formation: self-renewal
through cell-cycle changes, chromatin reprogram-
ming that possibly influences differentiation or the
subsequent activity of the other three factors, and
selection of a rare permissive cell. Also a combina-
tion model is presented at the bottom incorporat-
ing aspects of the individual models into a step-
wise process.
NSCs, which exhibit enhanced neuronal
differentiation. Reprogramming fibro-
blasts to iPS cells is a taller order than
blocking differentiation, likely requiring
the reversal of a pre-existing differenti-
ated stateby excessmyc. Suchaprocess
would also unfortunately bring the cells
one step closer to oncogenic transforma-
tion. Alternatively, Myc may facilitate the
iPS cell process by setting the stage, at
a chromatin level, for subsequent activity
of other factors (see combination model
below) such as Nanog, Oct3/4, Sox2, or Klf4, as chromatin struc-
ture appears of central importance to ESC biology (Bernstein
et al., 2006).
Selection of a Rare Population
It is also possible that among millions of fibroblasts lurk rare
stem-like cells that are not fully differentiated and represent
the only target cells amenable to direct reprogramming into
iPS cell clones. This interpretation could explain why less than
1% of cells transduced with the four factors are selected
in iPS cell induction protocols (Takahashi and Yamanaka,
2006). Such pluripotency-competent or permissive cells may
require only inhibition of differentiation rather than its reversal
by myc. If such a unique nonfibroblast pluripotency-competent
cell were indeed the true source of iPS cells, it would suggest
there may be a higher hurdle for developing potential future
patient-specific regenerative medicine therapies, as the bulk of
available fibroblasts are not able to do the trick. Thus, resolving
the cell of origin of iPS cells is of great importance. However, the
rarity of iPS cell events may instead be related to technical
issues such as a dependence on specific viral integration sites,
which may influence the expression levels of the four genes.
For example, levels of myc that are too high are likely to trigger
apoptosis (Cartwright et al., 2005), whereas very low expression
would inhibit induction of pluripotency. Finally, as yet unidenti-
fied factors, expressed in rare cells in the fibroblast population,
may also be essential. Testing other cell types besides fibro-
blasts for their ability to be transformed into iPS cells should
address some of these issues and may lead to the discovery
of a cell of origin with iPS cell forming capacity dramatically
higher than fibroblasts.
A Combination Model
A fourth possibility as to the role of myc in iPS cells is that some
combination of the three models could be operative, given that
the individualcomponentsarenotmutuallyexclusive.Forexample,
Myc may cooperate with Klf4 to induce and maintain self-renewal20 Cell Stem Cell 2, January 2008 ª2008 Elsevier Inc.
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et al., 2007). In addition,Mycmayalsomodulatewidespread chro-
matin,making it competent for the actionof other factors, including
Nanog, Oct3/4, and Sox2 (Figure 1, bottom). Functional genomic
studies of Myc in stem and iPS cells will likely soon resolve how
Myc regulates chromatin and its possible importance for stem
cell biology.Comparingdata fromsuchstudieswithgenomicstud-
ies onOct3/4, Sox2, Klf4, and Nanog should elucidate their poten-
tial cooperative activities on chromatin and gene expression. An-
other important step for addressing a combinatorial model is an
analysis of whether the order inwhich these factors are introduced
influences iPS cell formation.
Future Perspectives: Opposing Roles formyc
in Regenerative Medicine
In the context of emerging regenerative medicine, myc has the
potential to play a ‘‘Dr. Jekyll/Mr. Hyde’’ or dual role in stem cells.
Some minimal level of myc expression is almost certain to be
essential for normal stem cell-mediated regenerative tissue
growth, and in that way, myc has a good side. However, even
a modest excess of myc, whether endogenous or exogenous,
in transplanted stem cells could be disastrous, as it may cause
tumors in recipient patients, possibly by promoting cancer
stem cell formation. To obtain the best of both worlds, another
notion is to conditionally expressmyc in transplanted stem cells
by using methods that allow its inactivation once regenerative
growth has been achieved. An inducible system such as a tetra-
cycline-controlled myc transgene is one example of a regulated
modification. Indeed, in mousemodels of this kind,myc-induced
tumors often disappear permanently once myc is shut off, dem-
onstrating the so-called ‘‘oncogene addiction’’ phenomenon
(Wu et al., 2007). Unfortunately, the loss ofmyc does not always
lead to sustained murine tumor regression, underscoring the
potential risk of utilizingmyc for the purpose of stem cell therapy.
Further, mice derived from the Nanog-iPS cells, in which all four
genes introduced in the induction cocktail had spontaneously
turned ‘‘off,’’ exhibited a substantial risk for tumors due to spon-
taneous reactivation of c-myc virus (Okita et al., 2007). Thus, any
elevation of myc levels, whether exogenous or resulting from
selection of the endogenous myc gene could make iPS cells
prone to induce tumors in patients receiving cell therapy.
The importance of myc for efficient iPS cell formation and its
key role in the biology of both ESCs andmany somatic stem cells
suggest shutting myc off altogether in stem cells—ESCs or iPS
cells—prior to transplant to attenuate the risk of cancer as
a side effect is unlikely to be compatible with successful regen-
erative medicine, because it will almost certainly yield nonfunc-
tional stem cells. Thus the key to safely utilizing stem cells in
regenerative medicine may reside in maintaining the appropriate
expression levels, neither too high nor too low, of myc. For cus-
tomized regenerative medicine using future iPS cell-like cells,
determining just how much myc, whether endogenous or exog-
enous, is both safe and effective as well as how to sustain that
level may be a necessary albeit challenging hurdle to jump. In
the end, it seems one way or another the field of regenerative
medicine will have to come to terms with myc, a previously un-anticipated friend and foe, to develop both safe and effective
therapies.
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Note Added in Proof
A related paper showing that iPS cells can be generated from human ES-,
fetal-, and adult-derived somatic cells, using three to six defined factors,
was published after this article was completed (Park, I.-H., Zhao, R., West,
J.A., Yabuuchi, A., Huo, H., Ince, T.A., Lerou, P.H., Lensch, M.W., and Daley,
G.Q. [2008]. Reprogramming of human somatic cells to pluripotency with
defined factors. Nature, in press. Published online November 23, 2008.
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